Gisele Dion - 16 Jul 2024 Form 4 Insider Report for Inhibikase Therapeutics, Inc. (IKT)

Reporting relationship: Director
Issuer ticker: IKT
Reported as of: 16 Jul 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Jul 2024, 17:23:53 UTC
Prior SEC filing: 05 Jul 2023
Source filing: View source filing
Reporting owner signature: /s/ Milton H. Werner, attorney-in-fact

Key filing fact

Gisele Dion filed Form 4 for Inhibikase Therapeutics, Inc. (IKT) on 18 Jul 2024.

Key facts

This page summarizes Gisele Dion's Form 4 filing for Inhibikase Therapeutics, Inc. (IKT).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 18 Jul 2024, 17:23.

Change

Previous filing in this sequence was filed on 05 Jul 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IKT transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +30,000
Change %
Price: $0.000000
Shares after: 30,000
Date: 16 Jul 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 30,000
Exercise price: $1.54
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The options will vest on the earlier of July 16, 2025 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.